Lexpos News

NHS England has announced that from December 2024, the Electronic Prescription Service (EPS) will be extended to Detained Estate healthcare services in England. This extension will allow prescribers working in prisons to issue EPS ‘To Take Out’ (TTO) and urgent prescriptions electronically to community pharmacies, removing the need for the use of paper FP10 forms. [...]

The post EPS rolls out for Detained Estate prescribers appeared first on Community Pharmacy England.

The following price concessions granted in November 2024 have rolled over to December 2024: Drug Pack size Price concession Desloratadine 5mg tablets 30 £4.56 Travoprost 40micrograms/ml / timolol 5mg/ml eye drops 2.5 £10.59 Vardenafil 20mg tablets 4 £3.65 Please note any rolled over prices can be adjusted upwards if we receive reports from pharmacy owners [...]

The post Rolled over price concessions for December 2024 appeared first on Community Pharmacy England.

Community Pharmacy England has urged Ministers to provide immediate funding relief to community pharmacies and warning that without this, pharmacy closures will continue, with the potential for a house of cards collapse of the sector. Writing to Ministers, Chief Executive Janet Morrison warned that without remedial action soon, there will not be a community pharmacy [...]

The post Inject funding now to prevent collapse, CPE tells Ministers appeared first on Community Pharmacy England.

Community Pharmacy England CEO Janet Morrison has given a video update on the Community Pharmacy Contractual Framework (CPCF) negotiations, addressing the prolonged pause that means the sector is still without an agreement for 2024/25. In her video message, Janet addresses the continued delay in recommencing negotiations, describing the “severe frustration and intense anger” that the [...]

The post CPCF Negotiations Update: A message from our CEO appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Information: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) Drug alert number: EL (24)A/61 Date issued: 4 December 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) DMRC reference number:DMRC-34033472 Company [...]

The post MHRA Class 4 Medicines Defect Information: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) appeared first on Community Pharmacy England.